The molecular epidemiology of group A streptococcal pharyngeal infections in children in the Vanguard Community of Cape Town revealed 26 emm types among 157 isolates from 742 subjects. Coverage of a 30-valent vaccine is predicted to be 95% of pharyngitis cases in this population at high risk of rheumatic fever.
Supplemental Digital Content is available in the text.
From the *Department of Medicine, Groote Schuur Hospital and University of Cape Town; †Department of Clinical Laboratory Sciences, Division of Microbiology, National Health Service and University of Cape Town, Cape Town, South Africa; and ‡University of Tennessee Health Science Center, Memphis, TN.
Accepted for publication July 18, 2013.
M.E.E. and B.M. contributed equally to this work.
J.B.D. is the inventor of certain technologies related to the development of GAS vaccines. The University of Tennessee Research Corporation has licensed the technology to Vaxent, LLC. J.B.D. serves as the Chief Scientific Officer of Vaxent and has a financial interest in the LLC. This work was supported by the USPHS National Institutes of Health, UO1AI060592 and RO1AI010085 to J.B.D. and the South African Medical Research Council to M.E.E. and B.M.M. The authors have no other funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: James B. Dale, MD, University of Tennessee Health Science Center, 956 Court Avenue, Room E332, Memphis, TN 38163. E-mail: firstname.lastname@example.org.